Cargando…
Antiviral drugs
This chapter discusses the adverse effects of antiviral drugs used against cytomegalovirus, herpesviruses, hepatitis viruses, against HIV, and against influenza viruses. The cidofovir, drug active against cytomegalovirus, has been associated with bronchiolitis obliterans. Aciclovir and valaciclovir...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7148789/ http://dx.doi.org/10.1016/S0378-6080(10)32029-0 |
_version_ | 1783520669450895360 |
---|---|
author | Koch, Oliver Sheehy, Susanne Sargent, Catherine Democratis, Jane Abbas, Sarah Schiefermueller, Jurgen Angus, Brian J. |
author_facet | Koch, Oliver Sheehy, Susanne Sargent, Catherine Democratis, Jane Abbas, Sarah Schiefermueller, Jurgen Angus, Brian J. |
author_sort | Koch, Oliver |
collection | PubMed |
description | This chapter discusses the adverse effects of antiviral drugs used against cytomegalovirus, herpesviruses, hepatitis viruses, against HIV, and against influenza viruses. The cidofovir, drug active against cytomegalovirus, has been associated with bronchiolitis obliterans. Aciclovir and valaciclovir has been reported with renal insufficiency. Adefovir , a drug active against hepatitis viruses, is associated with the fall in creatinine clearance in patients with lamivudine-resistant HBe antigen (HBeAg)negative disease. Drugs active against HIV are comprehensively reviewed as in combination, nucleoside analogue reverse transcriptase inhibitors, nucleoside analogue reverse transcriptase inhibitors, and protease inhibitors. In a randomized controlled trial of indinavir, saquinavir and lopinavir in combination with low-dose ritonavir in 656 patients, median total cholesterol increased by 0.5 mmol/l in the patients with the highest minimum drug plasma concentrations. In patients with AIDS-associated AIDS dementia complex taking optimal stable background antiretroviral therapy including either abacavir or placebo, there was significantly more nausea in those who took abacavir. |
format | Online Article Text |
id | pubmed-7148789 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | Elsevier B.V. |
record_format | MEDLINE/PubMed |
spelling | pubmed-71487892020-04-13 Antiviral drugs Koch, Oliver Sheehy, Susanne Sargent, Catherine Democratis, Jane Abbas, Sarah Schiefermueller, Jurgen Angus, Brian J. Side Effects of Drugs Annual Article This chapter discusses the adverse effects of antiviral drugs used against cytomegalovirus, herpesviruses, hepatitis viruses, against HIV, and against influenza viruses. The cidofovir, drug active against cytomegalovirus, has been associated with bronchiolitis obliterans. Aciclovir and valaciclovir has been reported with renal insufficiency. Adefovir , a drug active against hepatitis viruses, is associated with the fall in creatinine clearance in patients with lamivudine-resistant HBe antigen (HBeAg)negative disease. Drugs active against HIV are comprehensively reviewed as in combination, nucleoside analogue reverse transcriptase inhibitors, nucleoside analogue reverse transcriptase inhibitors, and protease inhibitors. In a randomized controlled trial of indinavir, saquinavir and lopinavir in combination with low-dose ritonavir in 656 patients, median total cholesterol increased by 0.5 mmol/l in the patients with the highest minimum drug plasma concentrations. In patients with AIDS-associated AIDS dementia complex taking optimal stable background antiretroviral therapy including either abacavir or placebo, there was significantly more nausea in those who took abacavir. Elsevier B.V. 2010 2010-10-27 /pmc/articles/PMC7148789/ http://dx.doi.org/10.1016/S0378-6080(10)32029-0 Text en Copyright © 2010 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Koch, Oliver Sheehy, Susanne Sargent, Catherine Democratis, Jane Abbas, Sarah Schiefermueller, Jurgen Angus, Brian J. Antiviral drugs |
title | Antiviral drugs |
title_full | Antiviral drugs |
title_fullStr | Antiviral drugs |
title_full_unstemmed | Antiviral drugs |
title_short | Antiviral drugs |
title_sort | antiviral drugs |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7148789/ http://dx.doi.org/10.1016/S0378-6080(10)32029-0 |
work_keys_str_mv | AT kocholiver antiviraldrugs AT sheehysusanne antiviraldrugs AT sargentcatherine antiviraldrugs AT democratisjane antiviraldrugs AT abbassarah antiviraldrugs AT schiefermuellerjurgen antiviraldrugs AT angusbrianj antiviraldrugs |